Pharmacokinetics and efficacy of tank-water administered BRAF-inhibitor dabrafenib in a zebrafish model of BRAF-mutant melanomaJenna Villman, Kari J. Kurppa|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0
Recurrent cancer‐associated <scp>ERBB4</scp> mutations are transforming and confer resistance to targeted therapiesVeera K. Ojala, Kari J. Kurppa|Molecular Oncology|2025Cited by 0
YAP/TEAD drives treatment-induced adaptive immunosuppression in EGFR-mutant lung cancerMeija Honkanen, Kari J. Kurppa|bioRxiv (Cold Spring Harbor Laboratory)|2026Cited by 0